Hematology/oncology clinics of North America

The most recent articles from: Hematol. Oncol. Clin. North Am. August 2013

Hematol. Oncol. Clin. North Am. · Aug 2013

Review

Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.

B-cell receptor (BCR) signaling is essential for chronic lymphocytic leukemia (CLL) cell survival. Many kinases in the BCR signaling pathway are being studied as potential therapeutic targets. ⋯ Early clinical data in patients with CLL and non-Hodgkin lymphoma is encouraging. It is likely that ibrutinib and other drugs targeting the BCR pathway will become an integral component of CLL therapy.

expand abstract… or not…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,694,794 articles already indexed!